NASDAQ:IVF - US44984F6097 - Common Stock
The current stock price of IVF is 0.8435 USD. In the past month the price decreased by -50.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.1 | 231.15B | ||
ISRG | INTUITIVE SURGICAL INC | 56.46 | 162.94B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.91 | 158.98B | ||
SYK | STRYKER CORP | 30.69 | 150.76B | ||
MDT | MEDTRONIC PLC | 16.79 | 119.10B | ||
BDX | BECTON DICKINSON AND CO | 13.4 | 54.82B | ||
IDXX | IDEXX LABORATORIES INC | 53.33 | 51.24B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.5 | 47.53B | ||
RMD | RESMED INC | 28.67 | 40.09B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.91 | 33.84B | ||
DXCM | DEXCOM INC | 47.51 | 31.67B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.51 | 26.70B |
INVO Fertility, Inc. operates as a revenue-generating fertility business. The company is headquartered in Sarasota, Florida and currently employs 28 full-time employees. The company went IPO on 2008-11-11. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. The company focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. The company has two operational INVO Centers in the United States and one IVF clinic. The company is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
INVO FERTILITY INC
5582 Broadcast Court
Sarasota FLORIDA US
Employees: 28
Phone: 19788789505
The current stock price of IVF is 0.8435 USD. The price decreased by -9.3% in the last trading session.
The exchange symbol of INVO FERTILITY INC is IVF and it is listed on the Nasdaq exchange.
IVF stock is listed on the Nasdaq exchange.
5 analysts have analysed IVF and the average price target is 18.36 USD. This implies a price increase of 2076.64% is expected in the next year compared to the current price of 0.8435. Check the INVO FERTILITY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INVO FERTILITY INC (IVF) has a market capitalization of 3.68M USD. This makes IVF a Nano Cap stock.
INVO FERTILITY INC (IVF) currently has 28 employees.
INVO FERTILITY INC (IVF) has a resistance level at 1.19. Check the full technical report for a detailed analysis of IVF support and resistance levels.
The Revenue of INVO FERTILITY INC (IVF) is expected to grow by 10.02% in the next year. Check the estimates tab for more information on the IVF EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IVF does not pay a dividend.
INVO FERTILITY INC (IVF) will report earnings on 2025-11-17.
INVO FERTILITY INC (IVF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-69.64).
ChartMill assigns a fundamental rating of 2 / 10 to IVF. IVF has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months IVF reported a non-GAAP Earnings per Share(EPS) of -69.64. The EPS decreased by -309.16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -79.24% | ||
ROE | -343.9% | ||
Debt/Equity | 0.27 |
5 analysts have analysed IVF and the average price target is 18.36 USD. This implies a price increase of 2076.64% is expected in the next year compared to the current price of 0.8435.
For the next year, analysts expect an EPS growth of 92.84% and a revenue growth 10.02% for IVF